Acadia Pharmaceuticals will request a reexamination of a negative opinion recommending against approval of trofinetide, its oral therapy for Rett syndrome, in the European Union (EU). The therapy is already approved in the U.S., Canada, and Israel under the name Daybue. The opinion was issued by the Committee…